Paper · 41907306
Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.
Karunakar KK and 4 others. Pharm Sci Adv, 2026. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery. Papers, record 41907306. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41907306
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 42,898,092 | Corrigendum regarding previously published articles. | https://conductscience.org/library/papers/42898092 |
Source PubMed
References109
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,408,808 | Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3. | Eur J Med Chem | 2019 | https://conductscience.org/library/papers/31408808 | PubMed |
| 2 | 24,965,573 | The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. | J Clin Pharmacol | 2014 | https://conductscience.org/library/papers/24965573 | PubMed |
| 3 | 30,907,116 | Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. | Ann Pharmacother | 2019 | https://conductscience.org/library/papers/30907116 | PubMed |
| 4 | 41,518,320 | Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. | Indian J Dermatol Venereol Leprol | 2026 | https://conductscience.org/library/papers/41518320 | PubMed |
| 5 | 29,351,986 | A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. | Haematologica | 2018 | https://conductscience.org/library/papers/29351986 | PubMed |
| 6 | 38,532,270 | A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis. | CPT Pharmacometrics Syst Pharmacol | 2024 | https://conductscience.org/library/papers/38532270 | PubMed |
| 7 | 40,129,147 | CRISPR-Cas9: Transforming Functional Genomics, Precision Medicine, and Drug Development - Opportunities, Challenges, and Future Directions. | Curr Gene Ther | 2026 | https://conductscience.org/library/papers/40129147 | PubMed |
| 8 | 41,299,768 | Therapeutic potential and mechanistic insights into adipose-derived stem cells and mesenchymal stem cell-derived exosomes in patients with Crohn's disease-associated fistulas: challenges and future perspectives. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/41299768 | PubMed |
| 9 | 29,434,279 | Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. | Leukemia | 2018 | https://conductscience.org/library/papers/29434279 | PubMed |
| 10 | 23,648,271 | Targeted cancer immunotherapy. | Curr Opin Pharmacol | 2013 | https://conductscience.org/library/papers/23648271 | PubMed |
1 to 10 of 109
See all 109 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,941,825 | JAK-STAT Signaling: Mechanisms and Therapeutics in Stem Cell Biology. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941825 | PubMed |
| 42,603,219 | Emerging non-invasive tools for hair follicle assessment: a narrative review on hyperspectral and terahertz imaging. | Lasers Med Sci | 2026 | https://conductscience.org/library/papers/42603219 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| JAK2 | 3,717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| JAK3 | 3,718 | PubTator's text mining | https://conductscience.org/library/genes/3718 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41907306
GET https://conductscience.org/api/papers/v1/41907306/references?page=2